Search results
Jan 18, 2022 · TORONTO, ON – A new report funded by the Canadian Cancer Society (CCS) is renewing calls from patient organizations to fill the funding gap for take-home cancer drugs in Ontario.
The New Drug Funding Program (NDFP) directly covers the cost of many newer and often very expensive injectable cancer drugs. The Evidence Building Program covers the cost of cancer drugs in situations where data is collected to answer an evidence gap, to evaluate clinical benefit and to confirm overall value.
Feb 28, 2024 · The Canadian Cancer Society is calling on Ontario to fund take-home cancer drugs in the same way as medications to treat cancer that are administered through IV in hospital.
The decision about whether to fund a cancer drug, as with any drug, is based on the degree of medical benefit it provides, weighed against overall cost. There are several reasons why a new drug or indication may not receive funding approval: There is a lack of high-quality evidence of its effectiveness. The drug's medical benefit might be marginal.
Aug 26, 2021 · When you’re facing treatment for cancer, you may start hearing about infusion treatments, therapies, and clinics. Infusions are a way to deliver drugs and medications directly into the bloodstream instead of taking them as pills or liquids.
Feb 3, 2023 · The National Research Council of Canada is developing new ways to create immunotherapies for cancer patients. Some Canadians with aggressive B-cell leukemia or lymphoma cancers who do not respond well to existing treatments may now have new hope.
People also ask
Should Ontario Fund take-home cancer drugs?
Can patients fill the funding gap for take-home cancer drugs in Ontario?
How much does Ontario pay for cancer drugs?
Why is cancer so expensive?
Who pays for cancer drugs?
Does CancerCare Ontario reimburse hospitals for injectable cancer drugs?
Ontario. Cancer can be expensive to treat and manage. In a literature review conducted by the Canadian Cancer Society in 2010, findings showed that most of the costs incurred by patients and their families were traced back to travelling expenses, out-of-pocket costs, and cancer drugs and prescription medicines.
